{"id":1671,"date":"2023-02-15T13:30:22","date_gmt":"2023-02-15T12:30:22","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=1671"},"modified":"2023-02-15T12:42:30","modified_gmt":"2023-02-15T11:42:30","slug":"half-year-report-july-1-december-31-2022","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/half-year-report-july-1-december-31-2022\/","title":{"rendered":"Half-year report July 1 &#8211; December 31, 2022"},"content":{"rendered":"<div class=\"page\" title=\"Page 1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Summary of the second quarter (2022-10-01 \u2013 2022-12-31)<\/strong><\/p>\n<ul>\n<li>Net sales amounted to MSEK 0,0 (0,0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -1,2 (-1,1)<\/li>\n<li>Earnings per share* SEK -0.06 (-0.08)<\/li>\n<\/ul>\n<p>* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.<\/p>\n<p><strong>Summary of the first half-year (2022-07-01 \u2013 2022-12-31)<\/strong><\/p>\n<ul>\n<li>Net sales amounted to MSEK 0,0 (0,0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -2,0 (-2,1)<\/li>\n<li>Earnings per share* SEK -0.11 (-0.14)<\/li>\n<li>Cash and cash equivalents at the end of the period amounted to MSEK 30,4 (35,5)<\/li>\n<\/ul>\n<p>* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 15,366,150. Amounts in brackets refer to the corresponding period last year.<\/p>\n<p><strong>CEO&#8217;s comment<\/strong><\/p>\n<p>The application for a clinical phase 1 study regarding OsteoDex treatment of multiple myeloma was approved by the Swedish Medical Products Agency and permission was announced on August 10, 2022. The study will include 20 patients with multiple myeloma and be conducted at approximately 4\u20135 hospital centers in Sweden and the rest of the Nordic region.<\/p>\n<p>Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology\/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. The patients included have relapsed\/treatment-resistant disease and have received 1\u20133 prior lines of therapy. The primary objective is to confirm safety and tolerability and as a secondary objective to determine treatment response documented by changes in the level of disease-related biomarkers. Documentation of quality of life will also be done (QoL scores).<\/p>\n<p>Completion of study material (GMP manufactured OsteoDex) is underway at Biovian Turku, Finland, which is the company&#8217;s CMO. The study is expected to start in 2023 and is expected to be completed during Q3 2024.<\/p>\n<p>Anders R Holmberg<\/p>\n<p>CEO<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<p><a href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/Dextech-Half-year-report-July-December-2022.pdf\">Dextech &#8211; Half-year report July &#8211; December 2022<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary of the second quarter (2022-10-01 \u2013 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,2 (-1,1) Earnings per share* SEK -0.06 (-0.08) * Before [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1671","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Half-year report July 1 - December 31, 2022 | DexTech<\/title>\n<meta name=\"description\" content=\"Summary of the second quarter (2022-10-01 \u2013 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,2 (-1,1) Earnings\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/?p=1667\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Half-year report July 1 - December 31, 2022 | DexTech\" \/>\n<meta property=\"og:description\" content=\"Summary of the second quarter (2022-10-01 \u2013 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,2 (-1,1) Earnings\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/?p=1667\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-15T12:30:22+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/?p=1667\",\"url\":\"https:\/\/dextechmedical.com\/?p=1667\",\"name\":\"Half-year report July 1 - December 31, 2022 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2023-02-15T12:30:22+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"Summary of the second quarter (2022-10-01 \u2013 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,2 (-1,1) Earnings\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/?p=1667#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/?p=1667\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/?p=1667#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Half-year report July 1 &#8211; December 31, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Half-year report July 1 - December 31, 2022 | DexTech","description":"Summary of the second quarter (2022-10-01 \u2013 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,2 (-1,1) Earnings","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/?p=1667","og_locale":"en_US","og_type":"article","og_title":"Half-year report July 1 - December 31, 2022 | DexTech","og_description":"Summary of the second quarter (2022-10-01 \u2013 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,2 (-1,1) Earnings","og_url":"https:\/\/dextechmedical.com\/?p=1667","og_site_name":"DexTech","article_published_time":"2023-02-15T12:30:22+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/?p=1667","url":"https:\/\/dextechmedical.com\/?p=1667","name":"Half-year report July 1 - December 31, 2022 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2023-02-15T12:30:22+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"Summary of the second quarter (2022-10-01 \u2013 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,2 (-1,1) Earnings","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/?p=1667#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/?p=1667"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/?p=1667#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Half-year report July 1 &#8211; December 31, 2022"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=1671"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1671\/revisions"}],"predecessor-version":[{"id":1674,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1671\/revisions\/1674"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=1671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=1671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=1671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}